Benefits of ‘observer effects’: lessons from the field T Monahan, JA Fisher Qualitative Research 10 (3), 357-376, 2010 | 464 | 2010 |
Medical research for hire: the political economy of pharmaceutical clinical trials JA Fisher Rutgers University Press, 2009 | 345 | 2009 |
Challenging Assumptions About Minority Participation in US Clinical Research JA Fisher, CA Kalbaugh American journal of public health 101 (12), 2217-2222, 2011 | 321 | 2011 |
Tattooing the body, marking culture JA Fisher Body & society 8 (4), 91-107, 2002 | 320 | 2002 |
Tracking the social dimensions of RFID systems in hospitals JA Fisher, T Monahan International journal of medical informatics 77 (3), 176-183, 2008 | 314 | 2008 |
Treatment of overactive bladder in women KE Hartmann, ML McPheeters, DH Biller, RM Ward, JN McKoy, ... Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2009 | 183 | 2009 |
Strategies for Obtaining Access to Secretive or Guarded Organizations T Monahan, JA Fisher Journal of Contemporary Ethnography 44 (6), 709-736, 2015 | 145 | 2015 |
Expanding the Frame of "Voluntariness" in Informed Consent: Structural Coercion and the Power of Social and Economic Context JA Fisher Kennedy Institute of Ethics Journal 23 (4), 355-379, 2013 | 123 | 2013 |
Evaluation of real-time location systems in their hospital contexts JA Fisher, T Monahan International Journal of Medical Informatics 81 (10), 705-712, 2012 | 119 | 2012 |
Co‐ordinating ‘ethical’ clinical trials: the role of research coordinators in the contract research industry JA Fisher Sociology of health & illness 28 (6), 678-694, 2006 | 88 | 2006 |
Coming soon to a physician near you: Medical neoliberalism and pharmaceutical clinical trials JA Fisher Harvard health policy review 8 (1), 61, 2007 | 79 | 2007 |
“Ready-to-recruit” or “ready-to-consent” populations? Informed consent and the limits of subject autonomy JA Fisher Qualitative Inquiry 13 (6), 875-894, 2007 | 77 | 2007 |
Indoor positioning and digital management: Emerging surveillance regimes in hospitals JA Fisher Surveillance and security: Technological politics and power in everyday life …, 2006 | 71 | 2006 |
Peering into the pharmaceutical “pipeline”: investigational drugs, clinical trials, and industry priorities JA Fisher, MD Cottingham, CA Kalbaugh Social Science & Medicine 131, 322-330, 2015 | 64 | 2015 |
Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment GE Henderson, HL Peay, E Kroon, RJ Cadigan, K Meagher, T Jupimai, ... Journal of medical ethics 44 (4), 270-276, 2018 | 63 | 2018 |
Procedural misconceptions and informed consent: insights from empirical research on the clinical trials industry JA Fisher Kennedy Institute of Ethics Journal 16 (3), 251-268, 2006 | 59 | 2006 |
Adverse Events: Race, Inequality, and the Testing of New Pharmaceuticals JA Fisher New York University Press, 2020 | 58 | 2020 |
Feeding and bleeding: The institutional banalization of risk to healthy volunteers in phase I pharmaceutical clinical trials JA Fisher Science, Technology, & Human Values 40 (2), 199-226, 2015 | 54 | 2015 |
‘I'm still a hustler’: entrepreneurial responses to precarity by participants in phase I clinical trials T Monahan, JA Fisher Economy and Society 44 (4), 545-566, 2015 | 52 | 2015 |
Sex, gender, and pharmaceutical politics: from drug development to marketing JA Fisher, LM Ronald Gender medicine 7 (4), 357-370, 2010 | 51 | 2010 |